climat
chang
intern
travel
dramat
impact
geograph
distribut
pathogen
infect
human
anim
old
world
pathogen
dengu
chikungunya
viru
previous
restrict
middl
east
africa
asia
appear
america
newer
pathogen
middl
east
respiratori
syndrom
coronaviru
merscov
entir
new
coronaviru
affect
human
spread
beyond
region
world
deriv
name
meanwhil
human
popul
develop
area
world
continu
threaten
neglect
tropic
diseas
ntd
two
billion
peopl
nearli
world
popul
suffer
one
ntd
includ
leishmaniasi
lymphat
filariasi
onchocerciasi
schistosomiasi
soiltransmit
helminthiasi
among
other
tabl
addit
climat
chang
airlin
travel
econom
condit
lead
transmigr
contribut
spread
ntd
recent
exampl
includ
reemerg
leishmania
spain
chaga
diseas
texa
even
ntd
expand
reach
vaccin
develop
diseas
lag
behind
contrast
vaccin
import
emerg
infecti
diseas
eid
tabl
develop
certain
extent
larg
biotechnolog
compani
particularli
compani
receiv
guarante
purchas
agreement
incent
acceler
vaccin
develop
exampl
includ
develop
vaccin
emerg
avian
influenza
novarti
novavax
work
toward
develop
new
merscov
vaccin
howev
standard
approach
develop
new
vaccin
emerg
reemerg
infecti
diseas
threat
implement
previous
exist
vaccin
design
methodolog
clone
express
domin
surfac
antigen
frequent
result
develop
vaccin
effect
given
strong
adjuv
approach
particularli
unlik
work
pathogen
complex
lifecycl
parasit
highli
mutabl
rna
virus
articl
discuss
new
comput
approach
may
acceler
improv
design
vaccin
ntd
eid
truli
effect
vaccin
exist
major
ntd
although
vaccin
develop
sever
ntd
pathogen
lack
financi
incent
invest
research
develop
program
diseas
concentr
lowincom
countri
mire
progress
vaccin
effort
among
larg
pharmaceut
compani
prevent
chemotherapi
mass
drug
administr
mda
program
employ
donat
extrem
lowcost
gener
drug
current
progress
control
lymphat
filariasi
onchocerciasi
leprosi
trachoma
helminthias
mani
area
world
complic
inher
strategi
region
affect
differ
ntd
overlap
coinfect
difficult
manag
antiparasit
agent
success
longterm
effort
offtarget
effect
masserad
campaign
individu
popul
level
remain
determin
observ
polio
geopolit
upheav
may
hamper
global
effort
erad
ntd
thu
effect
ntd
vaccin
still
need
new
design
methodolog
help
bridg
gap
great
need
vaccin
return
invest
pharmaceut
compani
fortun
genom
mani
newli
emerg
pathogen
neglect
tropic
diseaseassoci
pathogen
becom
avail
due
research
effort
worldwid
avail
genom
make
possibl
appli
comput
vaccinolog
tool
diseas
global
health
import
describ
follow
section
comput
tool
use
identifi
protein
antigen
interest
directli
genom
pathogen
theori
minim
set
antigen
epitop
induc
compet
immun
respons
pathogen
discov
use
new
tool
adjuv
trigger
innat
immun
essenti
compon
protect
immun
respons
direct
toward
inflamm
rather
toler
combin
minimum
antigen
compon
compris
payload
genomederiv
vaccin
deliv
right
vehicl
may
trigger
protect
immun
respons
fundament
principl
genomederiv
epitopedriven
vaccin
approach
illustr
tthu
import
epitop
key
determin
protect
immun
respons
reflect
flurri
immunoinformat
activ
past
decad
number
tcell
epitop
map
tool
develop
acceler
identif
critic
compon
immun
respons
use
method
frequenc
analysi
support
vector
machin
hidden
markov
model
neural
network
research
develop
highli
accur
tool
model
mhcpeptid
interfac
predict
tcell
epitop
avail
tool
comprehens
review
see
brusic
et
al
de
groot
martin
sett
et
al
concept
first
call
vaccinom
brusic
petrovski
revers
vaccinolog
rappuoli
recent
immunomederiv
genomederiv
vaccin
design
pederson
de
groot
martin
doytchinova
taylor
flower
comput
vaccinologist
unabl
success
develop
accur
tool
bcell
epitop
predict
even
though
one
commonli
measur
outcom
vaccin
accept
determin
protect
antibodi
gener
thu
current
comput
vaccinolog
approach
vaccin
develop
must
take
bcell
respons
consider
develop
approach
includ
mean
stimul
effect
humor
immun
requir
protect
challeng
given
tcell
depend
essenti
featur
effect
antibodi
respons
includ
bcell
affin
matur
class
switch
recombin
plasma
cell
differenti
memori
bcell
differenti
tcell
epitop
analysi
quantif
use
group
proxi
identifi
good
bcell
immunogen
link
silico
sequenc
analysi
desir
put
bcell
respons
one
first
question
face
comput
vaccinologist
priorit
search
antigen
protein
epitop
subunit
entir
set
protein
deriv
pathogen
genom
unlik
point
departur
epitop
map
sinc
mani
protein
may
part
core
genom
set
bacteri
viral
strain
pathogen
other
may
protein
serv
housekeep
gene
also
well
conserv
harmless
commens
organ
hand
protein
highli
conserv
across
variant
strain
pathogenspecif
upregul
interact
host
particularli
secret
pathogen
presum
attempt
alter
host
environ
excel
target
vaccin
develop
addit
target
upregul
secret
pathogenspecif
antigen
mean
select
antigen
epitop
screen
includ
identifi
protein
common
virul
compar
avirul
strain
select
gene
differenti
express
immunopathogenesi
priorit
protein
expos
surfac
pathogen
focus
protein
express
earli
cours
natur
infect
expert
protein
analysi
system
expasi
proteom
server
swiss
institut
bioinformat
offer
wide
varieti
proteom
tool
use
purpos
includ
tool
relat
protein
identif
character
group
adapt
approach
first
describ
gennaro
et
al
mycobacterium
tuberculosi
mtb
employ
seri
expasi
tool
signalp
tmpred
prosit
scan
triag
pathogen
genom
reduc
number
potenti
target
thousand
protein
sever
dozen
candid
antigen
first
test
approach
found
subset
epitop
deriv
mtb
genom
elicit
respons
mtbexpos
human
sampl
prototyp
epitopebas
tb
vaccin
shown
robustli
immunogen
murin
studi
set
antigen
select
use
method
describ
tool
avail
ivax
toolkit
use
rank
protein
rel
immunogen
base
put
tcell
epitop
content
purpos
ivax
calcul
immunogen
score
repres
deviat
number
put
epitop
found
given
protein
number
would
expect
find
randomli
gener
protein
sequenc
take
care
adjust
protein
size
context
immunogen
score
zero
reflect
random
averag
put
epitop
content
posit
score
reflect
epitop
content
expect
neg
score
reflect
less
epitop
content
expect
larg
number
protein
sequenc
deriv
directli
genom
select
pathogen
order
potenti
class
ctl
class
ii
helper
class
class
ii
epitop
content
place
immunogen
scale
figur
tool
allow
research
quickli
rank
given
set
protein
rel
ie
rel
absolut
ie
rel
panel
known
immunogen
nonimmunogen
protein
term
experi
epitoperich
protein
good
vaccin
target
elicit
strong
antibodi
respons
thu
previous
state
tcell
epitop
content
use
proxi
overal
immunogen
potenti
antigen
select
particularli
complic
target
parasit
organ
due
compar
massiv
genom
multistag
life
cycl
rank
antigen
may
assist
select
better
target
exampl
figur
show
two
candid
antigen
deriv
b
malayi
caus
agent
lymphat
filariasi
whose
life
cycl
divid
multipl
larval
stage
includ
microfilari
stage
case
protein
identifi
potenti
vaccin
target
shown
contain
minim
tcell
epitop
content
immunogen
score
thu
may
less
success
vaccin
candid
contrast
b
malayi
ortholog
litomosoid
sigmodonti
antigen
implic
confer
protect
microfilari
infect
carri
substanti
tcell
epitop
content
score
immunogen
scale
rang
wellknown
immunogen
furthermor
illustr
case
b
malayi
frequent
find
evid
pathogen
appear
reduc
tcell
epitop
content
key
protein
avoid
human
immun
respons
epitop
delet
establish
mean
immun
evas
hiv
hcv
thu
mechan
may
also
relev
context
infect
associ
chronic
infect
caus
filaria
leishmania
chronic
ntd
particularli
stage
associ
chronic
parasit
parasit
persist
face
immun
pressur
discuss
addit
mean
immun
evas
uncov
comput
tool
tcell
epitop
short
linear
peptid
bind
mhc
molecul
engag
cell
receptor
tcr
activ
specif
popul
andor
lymphocyt
epitop
key
form
immunolog
synaps
antigenpres
cell
cell
tcr
produc
myriad
possibl
conform
much
like
antibodi
relat
mhc
bind
domin
event
immun
recognit
word
mhc
ligand
also
tcell
epitop
tcell
epitop
definit
mhc
ligand
mhcpeptid
interact
well
character
base
character
patternmatch
algorithm
epimatrix
develop
screen
protein
sequenc
peptid
bind
mhc
human
mhc
molecul
hla
among
variabl
protein
human
genom
variat
ensur
surveil
capabl
human
immun
system
broad
deepli
redund
make
immun
escap
mutat
difficult
pathogen
organ
fortun
allel
much
common
other
human
popul
bind
repertoir
mani
allel
significantli
overlap
focus
allel
common
human
popul
significantli
differ
repres
human
divers
hla
allel
group
supertyp
reduc
search
space
manag
number
evalu
six
class
supertyp
allel
cover
genet
background
human
worldwid
use
defin
ctl
epitop
b
b
class
ii
helper
epitop
map
panel
eight
common
allel
give
broad
helper
epitop
coverag
concept
supertyp
allel
gener
accept
wide
appli
vaccin
design
field
comput
vaccinolog
use
set
select
protein
antigen
start
point
ivax
use
epimatrix
pars
overlap
frame
overlap
last
eight
amino
acid
score
predict
bind
affin
panel
class
class
ii
hla
allel
epimatrix
algorithm
compar
amino
acid
sequenc
given
peptid
coeffici
contain
store
probabl
matric
produc
raw
score
order
compar
potenti
epitop
across
multipl
hla
allel
epimatrix
raw
score
convert
normal
z
scale
peptid
score
epimatrix
z
scale
typic
top
given
sampl
like
mhc
ligand
evid
anim
studi
suggest
number
epitop
requir
full
protect
small
defin
subset
thu
epitopedriven
vaccin
develop
group
gener
contain
payload
epitop
provid
broad
coverag
human
genet
background
combin
promiscu
class
ii
epitop
class
supertyp
epitop
possibl
attain
coverag
hla
human
popul
recent
develop
vaccin
design
includ
consider
epitop
induc
regulatori
suppress
immun
respons
group
investig
epitop
crossconserv
human
genom
associ
diminish
regulatori
immun
respons
use
recent
develop
tool
call
janusmatrix
first
determin
publish
effector
tcell
epitop
distinguish
report
regulatori
tcell
epitop
basi
tcrspecif
crossreact
potenti
human
genom
human
microbiom
janusmatrix
differ
wholesequ
align
tool
blast
basi
upon
tcell
receptor
homolog
pathogen
peptid
whose
tcrface
residu
ident
epitop
contain
multipl
self
may
recogn
cell
specif
human
protein
cours
even
though
mhcface
residu
may
differ
peptid
must
still
capac
bind
mhc
pathogen
sequenc
provid
bind
preserv
take
account
janusmatrix
compar
tcrface
contour
pathogen
ligand
genom
interest
identifi
match
therein
predict
bind
mhc
tcrhomolog
epitop
share
pathogen
human
pathogen
microb
uncov
remark
speed
use
janusmatrix
tool
explor
uncov
high
degre
host
human
homolog
virus
tend
establish
chronic
infect
human
ebv
cmv
furthermor
commens
virus
shown
contain
significantli
human
genomehomolog
epitop
rel
caus
acut
infect
eg
ebola
marburg
limit
clinic
efficaci
vaccin
select
microbi
pathogen
may
fact
due
extens
crossconserv
human
genom
janusmatrix
tool
current
use
team
collabor
identifi
signific
homolog
candid
payload
epitop
protein
contain
within
human
genom
human
microbiom
use
tool
find
virus
also
bacteria
establish
chronic
infect
human
deimmun
remov
tcell
epitop
toler
modifi
epitop
crossreact
human
tcell
epitop
comprehens
studi
ntd
genom
stagebystag
analysi
parasit
antigen
perform
use
janusmatrix
tool
near
futur
follow
care
select
tcell
epitop
redesign
whole
antigen
avoid
inclus
tcell
epitop
may
highli
crossreact
human
genom
could
improv
efficaci
wholeantigen
epitopebas
vaccin
janusmatrix
complement
recent
research
develop
adapt
immun
support
hypothesi
adapt
tcell
respons
reinforc
crossreact
human
microbiom
cytoscap
onlin
tool
usual
use
bioinformatician
illustr
related
protein
exampl
intracellular
protein
might
involv
stimul
cell
tolllik
receptor
repurpos
cytoscap
describ
relationship
epitop
across
protein
group
sequenc
human
genom
human
microbiom
pathogen
genom
use
cytoscap
result
janusmatrix
analysi
eg
compar
pathogen
epitop
human
genom
visual
network
epitop
deriv
pathogen
link
tcrmatch
counterpart
search
databas
link
sourc
protein
exampl
influenza
tcell
epitop
previous
identifi
mark
davi
colleagu
stimul
cell
subject
never
expos
influenza
shown
extens
network
crossreact
tcrface
epitop
human
microbiom
contrast
epitop
vaccinia
viru
synthes
test
larri
stern
group
shown
extens
crossreact
human
genom
janusmatrix
epitop
nonimmunogen
vitro
elispot
even
though
shown
bind
correct
class
ii
mhc
epitop
fit
emerg
silico
definit
treg
epitop
due
commens
natur
need
avoid
human
immun
respons
mani
year
coexist
even
like
select
human
parasit
share
put
tcell
epitop
content
human
host
figur
offer
two
exampl
peptid
b
malayi
antigen
compar
publish
treg
epitop
human
immunoglobulin
tregitop
effector
epitop
ceft
pool
set
peptid
use
control
posit
peptid
elispot
potenti
crossreact
network
differenti
evid
epitop
mani
relat
epitop
deriv
human
sequenc
sequenc
whose
relat
human
epitop
find
underscor
import
valid
respons
phenotyp
cell
stimul
epitop
identifi
silico
prior
inclus
vaccin
construct
also
illustr
import
type
analysi
select
candid
epitop
ntd
promiscu
hla
bind
potenti
featur
class
iirestrict
tcell
epitop
particularli
exploit
vaccin
design
purpos
shown
put
epitop
hla
class
ii
often
distribut
evenli
across
protein
sequenc
instead
tend
cluster
specif
region
uncommon
observ
sever
reactiv
frame
close
proxim
cluster
unusu
high
predict
epitop
densiti
identifi
silico
use
clustim
algorithm
gener
tcell
epitop
cluster
identifi
clustim
algorithm
tend
promiscu
mhc
binder
frequent
tcell
epitop
due
overlap
peptidebind
prefer
among
hladr
allel
also
possibl
identifi
singl
capabl
bind
four
hla
allel
sequenc
dub
epibar
due
horizont
bandlik
signatur
readout
epimatrix
figur
tcell
epitop
cluster
power
epibar
may
characterist
featur
highli
immunogen
promiscu
class
ii
epitop
compact
highli
reactiv
peptid
rel
easi
deliv
show
great
promis
vaccin
compon
crossreact
human
genom
limit
see
use
cluster
extens
work
promiscu
tcell
epitop
also
exist
certain
degre
class
allel
howev
much
less
common
class
ii
laboratori
demonstr
crosspresent
peptid
within
hla
superfamili
superfamili
crossmhc
bind
present
cell
confirm
hiv
vaccin
studi
howev
found
weight
toward
select
highli
promiscu
class
epitop
may
lead
identif
candid
epitop
lower
bind
affin
overal
higher
bind
affin
appear
critic
aspect
ctl
epitop
efficaci
thu
group
prefer
select
small
set
bestscor
put
epitop
six
class
hla
superfamili
given
protein
set
conserv
peptid
figur
select
epitop
broadli
reactiv
across
circul
strain
enhanc
broad
applic
new
vaccin
problem
pathogen
variabl
significantli
complic
select
epitop
vaccin
design
address
problem
epivax
develop
epiassembl
identifi
set
overlap
conserv
immunogen
epitop
assembl
extend
immunogen
consensu
sequenc
ic
figur
theori
behind
develop
ic
process
present
sequenc
would
allow
present
highli
conserv
class
iirestrict
epitop
contain
ic
context
one
mhc
result
peptid
pseudosequ
sinc
constitu
epitop
occur
correspond
posit
nativ
protein
adjac
epitop
may
similarli
conserv
variant
pathogen
ic
approach
use
identifi
highli
immunogen
epitop
hiv
vaccin
design
use
hiv
exampl
full
composit
ic
peptid
happen
exactli
conserv
individu
strain
hiv
peptid
repres
signific
percentag
circul
strain
everi
constitu
overlap
epitop
conserv
larg
number
rang
individu
strain
extend
approach
describ
possibl
develop
complet
synthet
antigen
whose
sequenc
optim
helper
potenti
eye
structur
consider
even
recombin
proteinonli
vaccin
could
optim
way
enabl
primari
cognat
help
maxim
bcell
memori
elicit
ideal
vaccin
might
includ
whole
protein
addit
epitop
antigen
could
optim
use
ic
approach
link
ic
epitop
carrier
protein
surfac
protein
target
bcell
respons
would
maxim
primari
cognat
help
sinc
b
cell
captur
recombin
protein
would
abl
process
present
helper
epitop
deriv
variabl
protein
compar
ic
randomli
select
counterpart
averag
contain
half
mani
bind
motif
cover
onethird
fewer
isol
develop
vaccin
equival
antigen
payload
use
convent
method
would
prohibit
expens
would
requir
use
multipl
variant
antigen
believ
similar
approach
har
conserv
help
tremend
potenti
deserv
care
consider
vaccin
design
gener
preliminari
list
candid
vaccin
compon
next
step
ivax
approach
review
put
epitop
produc
epimatrix
system
ad
qualit
quantit
annot
wherev
possibl
lead
investigatordriven
downselect
process
put
epitop
deriv
known
antigen
protein
overexpress
earli
stage
infect
protein
known
expos
immun
surveil
report
literatur
may
priorit
furthermor
put
epitop
silico
profil
potenti
regulatori
tcell
epitop
base
janusmatrix
analysi
remov
consider
algorithm
also
help
interpret
vaccin
compon
respons
preclin
clinic
studi
studi
immun
respons
therapeut
protein
vaccin
author
observ
subjecttosubject
variat
tcell
respons
close
relat
subject
hla
type
number
motif
peptid
match
subject
hla
haplotyp
describ
relationship
epivax
research
develop
metric
may
use
clinic
assess
immun
respons
vaccin
call
individu
tcell
epitop
measur
item
given
tcell
epitop
individu
item
score
calcul
weight
sum
epitop
epimatrix
zscore
hla
allel
given
subject
haplotyp
calcul
score
allow
individu
immunogen
potenti
predict
base
number
put
epitop
contain
protein
given
individu
hla
haplotyp
use
score
possibl
analyz
contribut
haplotyp
correspond
tcell
respons
prospect
retrospect
evalu
signific
correl
found
respons
given
antigen
item
score
individu
subject
addit
correl
item
score
patient
hla
observ
antibodi
titer
reflect
import
hlarestrict
tcell
respons
genesi
robust
antidrug
antibodi
respons
number
method
enhanc
epitopebas
vaccin
describ
implement
one
approach
align
individu
epitop
protein
dna
vaccin
construct
string
bead
without
interven
sequenc
spacer
payload
epitop
howev
lack
spacer
payload
epitop
rais
concern
sequenc
may
contain
junction
epitop
vaccinecad
algorithm
iter
analyz
epitop
assembl
minim
potenti
junction
immunogen
stringofbead
construct
develop
address
concern
peptid
sequenc
contain
junction
region
target
epitop
evalu
potenti
immunogen
highest
score
junction
identifi
algorithm
optim
order
epitop
evalu
potenti
altern
sequenc
process
repeat
addit
reduct
junction
immunogen
achiev
junction
immunogen
potenti
elimin
potenti
junction
immunogen
suffici
reduc
cleavag
promot
spacer
sequenc
typic
aay
class
restrict
construct
bind
inhibit
breaker
sequenc
gpgpg
class
ii
restrict
construct
place
two
offend
epitop
abil
minim
junction
immunogen
simultan
minim
presenc
transmembran
domain
highli
hydrophob
peptid
segment
may
difficult
express
would
logic
extens
tool
capabl
integr
comput
tool
epitop
discoveri
enabl
develop
genomederiv
vaccin
compar
convent
strategi
approach
potenti
creat
effect
safer
nextgener
vaccin
care
select
epitop
focu
immun
respons
minim
essenti
pathogenspecif
antigen
element
epitop
direct
conserv
self
host
antigen
elimin
approach
also
well
suit
highli
variabl
pathogen
select
epitop
conserv
across
multipl
strain
subtyp
enabl
develop
broadli
applic
multipathogen
vaccin
genomederiv
vaccin
strategi
appli
team
wide
rang
pathogen
includ
f
tularensi
variola
hiv
mtb
h
pylori
influenza
studi
demonstr
immunoinformaticpredict
epitop
immunoreact
vaccine
survivor
infect
stimul
de
novo
protect
immun
respons
vivo
hla
transgen
mice
eg
epitopedriven
vaccin
offer
distinct
advantag
tradit
subunit
vaccin
multipl
epitop
deriv
sever
antigen
packag
togeth
thu
broadbas
immun
respons
direct
sever
differ
antigen
protein
elicit
without
manufactur
administ
entir
protein
much
immunolog
irrelev
may
reduc
formul
challeng
cost
safeti
risk
use
epitop
also
mitig
safeti
concern
aris
use
intact
recombin
protein
may
undesir
biolog
activ
review
vaccin
design
tool
develop
epivax
team
mean
comprehens
mainli
focus
antigen
select
design
topic
cover
review
includ
formul
epitopedriven
vaccin
rout
deliveri
mucos
intraderm
etc
adjuv
select
deliveri
vehicl
preclin
clinic
test
major
caveat
concern
use
ivax
toolkit
none
vaccin
design
use
tool
advanc
clinic
given
cycl
vaccin
develop
surpris
may
take
year
develop
vaccin
full
industri
support
retrospect
prospect
studi
provid
extens
valid
tool
describ
nonetheless
algorithm
develop
appli
group
wide
rang
pathogen
met
signific
preclin
success
current
use
develop
vaccin
ntd
parasit
eid
virus
bioterror
pathogen
access
nearli
tool
describ
articl
freeli
avail
train
user
ivax
toolkit
websit
develop
fund
nation
institut
health
access
ivax
toolkit
train
tool
avail
interest
research
collabor
agreement
univers
rhode
island
primarili
ntd
arrang
possibl
commerci
user
direct
epivax
provid
secureaccess
version
ivax
websit
commerci
user
gener
field
vaccin
research
slow
adopt
new
vaccin
design
tool
even
fewer
ntd
research
familiar
use
tool
despit
proof
principl
genomederiv
vaccin
approach
fact
significantli
reduc
time
effort
make
vaccin
eid
tri
true
approach
often
win
newer
approach
even
though
tradit
approach
greater
likelihood
success
merscov
vaccin
develop
program
implement
illustr
principl
despit
fact
viru
belong
famili
coronavirus
histori
rapid
evolut
vaccin
approach
target
spike
protein
similar
approach
use
emerg
sar
complet
fail
protect
rapidli
evolv
sar
virus
anim
challeng
model
applic
advanc
immunoinformat
tool
ntd
vaccin
also
lag
number
reason
ntd
research
use
tool
lack
access
familiar
wide
public
exampl
focus
diseas
impact
develop
world
seri
technic
challeng
ntd
vaccin
describ
recent
includ
antigen
discoveri
process
develop
preclin
develop
clinic
trial
resourcepoor
set
immun
respons
ntd
infect
includ
commonli
refer
ige
trap
certain
individu
perhap
especi
endem
region
may
elev
preexist
ige
antibodi
potenti
ntd
vaccin
antigen
lead
increas
risk
vaccin
comput
vaccinolog
current
address
challeng
howev
approach
describ
offer
uniqu
opportun
address
certain
hurdl
earli
development
process
earli
pipelin
antigen
discoveri
use
tcell
epitop
predict
rank
along
candid
epitop
triag
use
cluster
analysi
crossreact
predict
provid
valuabl
lead
select
peptid
candid
screen
ex
vivo
order
verifi
phenotyp
immun
respons
prior
inclus
final
vaccin
product
final
tcell
epitopebas
strategi
except
platformflex
adapt
synthet
peptid
formul
deliver
salin
emuls
microparticl
encod
plasmid
vector
dna
vaccin
recombin
protein
product
thu
allow
novel
distribut
strategi
necessari
reach
world
poorest
flexibl
extend
antigen
discoveri
approach
well
mani
kind
target
may
explor
use
immunoinformat
tool
pertin
exampl
ntd
eid
appli
vectorbas
target
vaccin
compon
base
upon
salivari
protein
arthropod
vector
alreadi
investig
howev
vector
salivari
antigen
also
known
immunomodulatori
properti
allow
extend
host
toler
discoveri
evalu
strategi
describ
pathogen
antigen
could
appli
protein
potenti
provid
mechan
stimul
robust
immun
respons
absenc
immunomodulatori
properti
complet
salivari
antigen
amount
data
gener
new
technolog
nextgener
sequenc
continu
expand
exponenti
appli
technolog
studi
eid
ntd
caus
agent
expand
genom
knowledg
organ
feasibl
use
highthroughput
informaticsbas
tool
identif
put
protein
peptid
target
increas
vaccin
efficaci
may
also
improv
select
target
refin
compar
antigen
genom
sequenc
human
genom
human
microbiom
silicobas
approach
vaccin
design
may
also
allevi
mani
fundingassoci
challeng
common
tradit
vaccin
design
reduc
number
assay
need
perform
select
vaccin
target
reduc
cost
allow
realloc
critic
fund
test
silicopredict
target
construct
final
improv
safeti
elimin
human
genom
crossconserv
epitop
may
reduc
unwant
advers
effect
look
futur
confid
evolut
tool
describ
eventu
contribut
develop
person
ondemand
vaccin
consid
import
control
infecti
diseas
global
econom
stabil
integr
comput
vaccinolog
tool
applic
design
vaccin
ntd
eid
paramount
import
delay
longer
accept
vaccin
develop
must
implement
comput
vaccinolog
tool
wish
contribut
improv
world
health
centuri
